Intelligent Bio Solutions (NASDAQ:INBS) Posts Quarterly Earnings Results

Intelligent Bio Solutions (NASDAQ:INBS) announced its quarterly earnings data on Wednesday. The company reported ($0.35) EPS for the quarter, Zacks reports. Intelligent Bio Solutions had a negative return on equity of 231.13% and a negative net margin of 346.22%.

Intelligent Bio Solutions Stock Performance

Shares of NASDAQ INBS traded down $0.04 during trading on Wednesday, reaching $0.77. The stock had a trading volume of 187,260 shares, compared to its average volume of 210,318. The company has a market cap of $7.00 million, a P/E ratio of -0.38 and a beta of 4.49. The business’s 50-day moving average price is $1.19 and its 200-day moving average price is $1.45. Intelligent Bio Solutions has a fifty-two week low of $0.73 and a fifty-two week high of $2.75.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on INBS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Intelligent Bio Solutions from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.